Fig. 1: Kaplan–Meier plots of PFS according to ¹⁸F-FDG-PET/CT response and ctDNA detection 14 days after the start of treatment with exemestane-everolimus.

a PFS plots according to ¹⁸F-FDG-PET/CT response on D14: patients with >25% homogenous decrease in maximum standardized uptake value (SUVmax) in all target lesions are considered as “responders”. b PFS plots according to ¹⁸F-FDG-PET/CT response on D14: patients with a > 15 % homogenous decrease in maximum standardized uptake value (SUVmax) in all target lesions are considered as “responders”. This is a “post-hoc” analysis, initially not scheduled by the study protocol. c PFS according to ctDNA detection at baseline (40-gene targeted gene sequencing panel was realized in all plasma samples). d PFS according to ctDNA detection after 14 days of treatment with exemestane-everolimus. e PFS according to the combined analysis of ctDNA detection and ¹⁸F-FDG-PET/CT response when patients with >25% homogenous decrease in maximum standardized uptake value (SUVmax) in all target lesions are considered as “responders”. f Combined analysis of ctDNA detection and ¹⁸F-FDG-PET/CT response when patients with >15% homogenous decrease in maximum standardized uptake value (SUVmax) in all target lesions are considered as “responders”. The 15% cut-off is a “post-hoc” analysis, initially not scheduled by the study protocol. Log-Rank P values and LogRank Hazard ratios and 95% Confidence intervals for LogRank Hazard ratios for each test are displayed in each corresponding panel. For each group, the number at risk is presented under the X-axis. Consist criteria of ¹⁸F-FDG-PET/CT response is described Methods section, R = ¹⁸F-FDG-PET/CT responder; NR = ¹⁸F-FDG-PET/CT non-responder; ctDNA = circulating tumor DNA; D = ctDNA detected; ND = ctDNA not detected; D14 = 14 days after starting treatment with exemestane-everolimus.